Inc had its "buy" rating reiterated by analysts at Stifel Nicolaus. 01/23/2017 - Aegis Capital began new coverage on Concert Pharmaceuticals Inc giving the company a "buy" rating. Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 380.29 on Thursday.
Fifth Third Bancorp held its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, January 8th. Cowen and Company set a $430.00 target price
BTIG Research reissued their buy rating on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in a report and gave the company a buy rating in a research report on Saturday, February 11th. Robert W. Baird reiterated a neutral rating and set a